Primary biliary cirrhosis
Drug research and approvals for primary biliary cirrhosis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 36 studies of primary biliary cirrhosis are recruiting on ClinicalTrials.gov, Health Canada has authorized 7 drug trials for it since 2013, and FDA has 1 approved and 2 open orphan designations naming it.
- Recruiting worldwide: 36
- Trials authorized in Canada: 7
- FDA orphan approvals: 1
- EU medicines: 0
Recruiting Now
Newest start dates first, of 36 recruiting on ClinicalTrials.gov ↗- Study of Seladelpar and Cilofexor in Participants With Primary Biliary CholangitisNCT07841977 · Phase 2 · Gilead Sciences · starts Oct 1, 2026
- Study of Saroglitazar Magnesium for PBC Patients With Incomplete Response or Intolerant to UDCA TherapyNCT07424677 · Phase 3 · Zydus Therapeutics Inc. · starts Aug 11, 2026
- Elafibranor Pregnancy Surveillance Program: A Study to Evaluate the Safety of Elafibranor During PregnancyNCT07556913 · Not reported · Ipsen · starts Jul 29, 2026
- LEOPARD Prospective Validation Cohort 1NCT06723275 · Not reported · Assistance Publique - Hôpitaux de Paris · starts Jul 7, 2026
- Long-Term Study to Evaluate the Safety and Efficacy in Participants With Primary Biliary Cholangitis of Saroglitazar…NCT07216235 · Phase 3 · Zydus Therapeutics Inc. · starts Mar 24, 2026
- Austrian PBC RegistryNCT07598669 · Not reported · Medical University of Vienna · starts Mar 18, 2026
- Biochemical Response and Clinical Outcomes in Patients With PBCNCT07449793 · Not reported · RenJi Hospital · starts Feb 1, 2026
- FIREFLY Trial: Fenofibrate Intervention---Randomized Evaluation in First-Line PBC TherapyNCT07296458 · Phase 3 · Xijing Hospital of Digestive Diseases · starts Dec 15, 2025
- A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCANCT07282353 · Phase 3 · Cascade Pharmaceuticals, Inc · starts Dec 1, 2025
- Early Diagnosis of Primary Biliary Cholangitis (PBC) in Patients With Positive Anti-Mitochondrial Antibodies (AMA) and…NCT07205874 · Not reported · Hospital Universitario La Paz · starts Sep 15, 2025
Trials Authorized in Canada
Newest first; search them all in Canada trials| Jun 27, 2017 | A double-blind, randomized, placebo-controlled clinical trial to assess the efficacy and safety of oral gkt137831 in patients with primary biliary cholangitis…GKT137831 | GENKYOTEX SA | Closed |
| Feb 25, 2016 | A multi-part, randomized, double-blind, placebo-controlled study to assess the safety, tolerability and efficacy of ljn452 in patients with primary biliary…TROPIFEXOR (LJN452) | Novartis Pharmaceuticals Corporation | Ongoing |
| Sep 16, 2015 | A 12-week, double-blind, randomized, placebo-controlled, phase 2 study, to evaluate the effects of two doses of mbx-8025 in subjects with primary biliary…MBX-8025 | CYMABAY THERAPEUTICS INC | Ongoing |
| Jul 21, 2015 | A phase 3b, double blind, randomized, placebo controlled, multicenter study evaluating the effect of obeticholic acid on clinical outcomes in subjects with…OBETICHOLIC ACID (INT-747) | Alfasigma | Closed |
| Feb 10, 2015 | An open-label, multicenter extension study to evaluate the long-term safety and tolerability of lum001, an apical sodium-dependent bile acid transporter…LUM001 | LUMENA PHARMACEUTICALS INC | Closed |
| Jul 3, 2014 | A phase 2, randomized, double-blind, placebo-controlled study to evaluate lum001, an apical sodium-dependent bile acid transporter inhibitor (asbti), in…MARALIXIBAT (LUM001) | LUMENA PHARMACEUTICALS INC | Closed |
| Jun 21, 2013 | Pilot study of tenofovir and emtricitabine for primary biliary cirrhosisEMTRICITABINE/TENOFOVIR | GOVERNORS OF THE UNIVERSITY OF ALBERTA | Pending |
FDA Orphan Designations
Approved first, then open designations, newest first| Dec 10, 1997 | URSO 250Treatment of patients with primary biliary cirrhosis | Aptalis Pharma US, Inc. | Approved |
| Oct 31, 2012 | (2S)-2-{[(2R)-2-[({[3,3-dibutyl-7-(methylthio)-1,1-dioxido-5…Treatment of primary biliary cirrhosis | Ipsen Biopharmaceuticals, Inc. | Designated |
| Feb 19, 1991 | UrsodiolManagement of the clinical signs and symptoms associated with primary biliary cirrhosis. | Novartis Pharmaceuticals Corporation | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA